RJA
ANAB icon

Raymond James & Associates’s AnaptysBio ANAB Stock Holding History

Raymond James & Associates’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,275
Closed -$427K – 3544
2018
Q3 		$427K Sell
4,275
-700
-14% -$58.1K ﹤0.01% 2811
2018
Q2 		$353K Sell
4,975
-190
-4% -$15.9K ﹤0.01% 2917
2018
Q1 		$538K Buy
5,165
+1,925
+59% +$217K ﹤0.01% 2519
2017
Q4 		$326K Buy
+3,240
New +$239K ﹤0.01% 2781

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Raymond James & Associates's ANAB Position: Q4 2018 in Review

Raymond James & Associates sold out of AnaptysBio (ANAB) in Q4 2018, closing a stake of 4,275 shares — an estimated $427K sold.

Raymond James & Associates first reported a position in ANAB in Q4 2017 and held it in 4 quarters. The position peaked at $538K in Q1 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

  • Raymond James & Associates reported no remaining AnaptysBio position as of Q4 2018 after selling out during the quarter.
  • Raymond James & Associates sold 4,275 AnaptysBio shares in Q4 2018, an estimated $427K.
  • Raymond James & Associates first reported a position in AnaptysBio in Q4 2017 and held it in 4 quarters.
  • Raymond James & Associates's AnaptysBio position peaked at $538K in Q1 2018.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.